PL2498731T3 - Sposoby leczenia lub zapobiegania zakrzepicy w stencie - Google Patents

Sposoby leczenia lub zapobiegania zakrzepicy w stencie

Info

Publication number
PL2498731T3
PL2498731T3 PL10830654T PL10830654T PL2498731T3 PL 2498731 T3 PL2498731 T3 PL 2498731T3 PL 10830654 T PL10830654 T PL 10830654T PL 10830654 T PL10830654 T PL 10830654T PL 2498731 T3 PL2498731 T3 PL 2498731T3
Authority
PL
Poland
Prior art keywords
treating
methods
stent thrombosis
preventing stent
preventing
Prior art date
Application number
PL10830654T
Other languages
English (en)
Inventor
Clive Arthur Arculus-Meanwell
Simona Skerjanec
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43974647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2498731(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of PL2498731T3 publication Critical patent/PL2498731T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
PL10830654T 2009-11-11 2010-11-10 Sposoby leczenia lub zapobiegania zakrzepicy w stencie PL2498731T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26036109P 2009-11-11 2009-11-11
EP10830654.9A EP2498731B1 (en) 2009-11-11 2010-11-10 Methods of treating or preventing stent thrombosis
PCT/US2010/056225 WO2011060066A2 (en) 2009-11-11 2010-11-10 Methods of treating or preventing stent thrombosis

Publications (1)

Publication Number Publication Date
PL2498731T3 true PL2498731T3 (pl) 2020-07-13

Family

ID=43974647

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10830654T PL2498731T3 (pl) 2009-11-11 2010-11-10 Sposoby leczenia lub zapobiegania zakrzepicy w stencie

Country Status (13)

Country Link
US (4) US9925265B2 (pl)
EP (1) EP2498731B1 (pl)
AU (1) AU2010319612B2 (pl)
BR (1) BR112012011298B1 (pl)
CA (1) CA2778880C (pl)
DK (1) DK2498731T3 (pl)
EA (1) EA028885B1 (pl)
ES (1) ES2773040T3 (pl)
HR (1) HRP20200445T1 (pl)
PL (1) PL2498731T3 (pl)
PT (1) PT2498731T (pl)
SI (1) SI2498731T1 (pl)
WO (1) WO2011060066A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8680052B1 (en) 2013-03-09 2014-03-25 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
AU2010319612B2 (en) * 2009-11-11 2016-01-14 Chiesi Farmaceutici S.P.A. Methods of treating or preventing stent thrombosis
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112013020377B1 (pt) * 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
NZ708511A (en) * 2012-10-26 2018-11-30 Chiesi Farm Spa Methods for controlling blood pressure and reducing dyspnea in heart failure
EP2964233B1 (en) * 2013-03-09 2021-12-15 Chiesi Farmaceutici S.p.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2014142780A1 (en) * 2013-03-09 2014-09-18 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2014209389A1 (en) * 2013-06-26 2014-12-31 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
WO2015054542A1 (en) * 2013-10-09 2015-04-16 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2016114818A1 (en) * 2015-01-14 2016-07-21 The Medicines Company Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
EP3641784A1 (en) 2017-06-23 2020-04-29 Chiesi Farmaceutici S.p.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
DK0683789T3 (da) 1993-02-10 1998-02-09 Astra Pharma Prod N-alkyl-2-substituerede ATP-analoger
SE9604795D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
KR20030014294A (ko) 2000-07-06 2003-02-15 상꾜 가부시키가이샤 히드로피리딘 유도체 산부가염
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US20020123791A1 (en) * 2000-12-28 2002-09-05 Harrison William J. Stent design with increased vessel coverage
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
US7758630B2 (en) * 2003-04-14 2010-07-20 Tryton Medical, Inc. Helical ostium support for treating vascular bifurcations
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
WO2005087266A1 (en) * 2004-03-05 2005-09-22 Vddi Pharmaceuticals Combination therapy for inhibition of platelet aggregation
US20080214599A1 (en) 2005-08-19 2008-09-04 John Thomas Brandt Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases
DE102006020386A1 (de) 2006-04-28 2007-10-31 Dade Behring Marburg Gmbh Verfahren zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen
EP2041196B1 (en) * 2006-07-14 2012-11-28 Biocompatibles UK Limited Polymer
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
NZ580162A (en) 2007-04-13 2012-10-26 Millennium Pharm Inc Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
CN104800210B (zh) * 2007-04-27 2019-08-06 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
EP2079464A2 (en) 2007-05-02 2009-07-22 Portola Pharmaceuticals, Inc. Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
AU2008261691A1 (en) * 2007-06-11 2008-12-18 Nanovasc, Inc. Stents
US20090043380A1 (en) * 2007-08-09 2009-02-12 Specialized Vascular Technologies, Inc. Coatings for promoting endothelization of medical devices
US8998978B2 (en) * 2007-09-28 2015-04-07 Abbott Cardiovascular Systems Inc. Stent formed from bioerodible metal-bioceramic composite
US20110276123A1 (en) * 2007-11-27 2011-11-10 Davies Peter F Vascular stent design
CA2623449C (en) 2008-03-27 2010-11-02 Lance Baldo A novel use of bivalirudin in the treatment of acute coronary syndrome
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8680052B1 (en) * 2013-03-09 2014-03-25 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
KR101138294B1 (ko) * 2008-09-24 2012-04-25 김형일 혈관벽 임시 골격용 생분해성 블랜드
WO2011041217A1 (en) * 2009-10-02 2011-04-07 Schering Corporation The use of a par-1 antagonist in combination with a p2y12adp receptor antagonist for inhibition of thrombosis
AU2010319612B2 (en) * 2009-11-11 2016-01-14 Chiesi Farmaceutici S.P.A. Methods of treating or preventing stent thrombosis
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20130040898A1 (en) 2010-04-29 2013-02-14 Pär Johansson Methods of treatment of patients at increased risk of development of ischemic events and compounds hereof
CN103860459A (zh) 2012-12-11 2014-06-18 天津市汉康医药生物技术有限公司 一种坎格雷洛注射剂及其制备方法
WO2016114818A1 (en) * 2015-01-14 2016-07-21 The Medicines Company Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
EP3641784A1 (en) * 2017-06-23 2020-04-29 Chiesi Farmaceutici S.p.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis

Also Published As

Publication number Publication date
WO2011060066A9 (en) 2011-08-25
EA201270617A2 (ru) 2013-01-30
DK2498731T3 (da) 2020-03-02
BR112012011298B1 (pt) 2021-12-14
EP2498731B1 (en) 2020-01-22
ES2773040T3 (es) 2020-07-09
CA2778880A1 (en) 2011-05-19
EP2498731A2 (en) 2012-09-19
US20110112030A1 (en) 2011-05-12
US20190167796A1 (en) 2019-06-06
HRP20200445T1 (hr) 2020-06-12
AU2010319612A1 (en) 2012-05-24
US11147879B2 (en) 2021-10-19
EP2498731A4 (en) 2015-02-25
WO2011060066A2 (en) 2011-05-19
PT2498731T (pt) 2020-02-21
BR112012011298A2 (pt) 2019-09-24
US9925265B2 (en) 2018-03-27
EA028885B1 (ru) 2018-01-31
US20220008540A1 (en) 2022-01-13
US20240350638A1 (en) 2024-10-24
SI2498731T1 (sl) 2020-05-29
CA2778880C (en) 2018-02-13
AU2010319612B2 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
PL2498731T3 (pl) Sposoby leczenia lub zapobiegania zakrzepicy w stencie
IL239918A0 (en) Preparations for the treatment of colitis
EP2493309A4 (en) METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA
HK1217763A1 (zh) 用於治療疾病的方法
BRPI1008717A2 (pt) artigos e métodos de tratar condições vasculares.
IL208354A0 (en) Methods of treatment
EP2331564A4 (en) PROCESS FOR TREATMENT OF IGNITION
GB0915515D0 (en) Treatment of vasculoproliferative conditions
EP2613783A4 (en) METHODS OF TREATING OR PROPHYLAXISING THROMBOSIS OR EMBOLISM
EP2350641A4 (en) Methods of Treatment
EP2480579A4 (en) METHODS OF TREATING INFLAMMATION
IL206491A0 (en) Treatment of produce
DK2473482T3 (en) Methods of treating orthomyxoviral infections
IL215037A0 (en) Treatment of pancreatic cancer
EP2473193A4 (en) METHOD OF NERVE TISSUE MANIPULATION
IL218230A0 (en) Method of treating cancer
ZA201107820B (en) Compositions and methods for treatment of aortic fibrosis
EP2509599A4 (en) METHOD FOR THE TREATMENT OF PANCREATIC CANCER
EP2427053A4 (en) METHOD FOR TREATING THROMBOCYTOPENIA
EP2424539A4 (en) PROCESS FOR TREATING DEPRESSION
EP2440238A4 (en) Methods of Treatment
EP2393513A4 (en) METHOD FOR TREATING VESSELS
GB0921823D0 (en) Method of treatment
GB0909807D0 (en) Method of treatment
GB0904164D0 (en) Method of treatment